Abnormal bleeding in postmenopausal hormone users-What do we know today?

Maturitas

Volumn 63, Issue 1, 2009, Pages 45-50

  Hickey, Martha ^a   Ambekar, Manju ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b KING EDWARD MEMORIAL HOSPITAL   (Australia)

Author keywords

Estrogen; Hormone therapy; Menopause; Progestogen; Tibolone; Unscheduled bleeding

Indexed keywords

ESTROGEN; PLACEBO; PROGESTERONE; STEROID RECEPTOR; TIBOLONE;

ANGIOGENESIS; CELL POPULATION; CLINICAL FEATURE; DRUG EFFECT; ENDOMETRIUM; HEALTH CARE PERSONNEL; HEMOSTASIS; HORMONE SUBSTITUTION; HUMAN; LEUKOCYTE; LOW DRUG DOSE; OXYGENATION; PERFUSION; POSTMENOPAUSE; PROTEIN EXPRESSION; REVIEW; UTERUS BLEEDING; VASCULAR FRAGILITY; VASOMOTOR DISORDER;

ENDOMETRIUM; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; UTERINE HEMORRHAGE;

EID: 67349127523     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2009.03.010     Document Type: Review

References (64)

1. McLennan A.H., Lester S., and Moore V. Oral estrogen replacement therapy versus placebo for hot flushes. Cochrane Database Syst Rev 288 1 (2002) CD002978
2. Vickers M.R., Martin J., Meade T.W., and the WISDOM study team. Women's international study of long duration of estrogen after menopause. BMC Women's Health 7 (2007) 2 10.1186/1472-6874-7-2 Published online 2007, February 26
3. Al-Azzawi F., and Habiba M. Regular bleeding on hormone replacement therapy: a myth?. Br J Obstet Gynaecol 101 (1994) 661-662
4. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
5. Ettinger B., Li D.K., and Klein R. Unexpected vaginal bleeding and associated gynecologic care in postmenopausal women using hormone replacement therapy: comparison of cyclic versus continuous combined schedules. Fertil Steril 69 (1998) 865-869
6. Nagele F., O'Connor H., Basket T.F., et al. Hysteroscopy in women with abnormal uterine bleeding on hormone replacement therapy: a comparison with postmenopausal bleeding. Fertil Steril (1996) 65
7. Elliott J., Connor M.E., and Lashen H. The value of outpatient hysteroscopy in diagnosing endometrial pathology in postmenopausal women with and without hormone replacement therapy. Acta Obstet Gynecol Scand 82 (2003) 1112-1119
8. Sturdee D.W., Ulrich L.G., Barlow D.H., et al. The endometrial response to sequential and continuous combined oestrogen-progestogen replacement therapy. Br J Obstet Gynecol 107 (2001) 1392-1400
9. Archer D.F., Dorin M., Lewis V., et al. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. Fertil Steril 75 (2001) 1080-1087
10. The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women: the postmenopausal estrogen/progestin interventions trial. JAMA (1996) 275
11. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005;365(April(30)):1543-51.
12. Hickey M., Higham J.M., and Fraser I.S. Hormone replacement therapy and irregular bleeding. Climacteric 4 2 (2001) 95-101
13. Lethaby A., Suckling J., Barlow D., et al. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochrane Database Syst Rev 3 (2004) CD000402
14. Hillard T. Management of bleeding problems with hormone replacement therapy. J Fam Plann Reprod Health Care 28 4 (2002) 182-184
15. Bruce D., Robinson J., and Rymer J. Long-term effects of tibolone on the endometrium as assessed by bleeding episodes, transvaginal scan and endometrial biopsy. Climacteric 7 (2004) 261-266
16. Berning B., van Kuijk C., Bennink H.J., and Fauser B.C. Absent correlation between vaginal bleeding and oestradiol levels or endometrial morphology during tibolone use in early postmenopausal women. Maturitas 35 1 (2000) 81-88
17. Christodoulakos G.E., Botsis D.S., Lambrinoudaki I.V., et al. A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness. Maturitas 53 4 (2006) 413-423
18. Archer D.F., Hendrix S., Gallagher J.C., et al. J Clin Endocrinol Metab 92 3 (2007) 911-918 published
19. Cummings Sr., and Ettinger B. Long term interventions on fractures with tibolone LIFT study EM, Johnson S, Zanchetta J, Grobbee DE, Seifert W, Eastell R; LIFT Trial Investigators. N Engl J Med 14 August(359(7)) (2008) 697-708
20. Hickey M., Pillai G., Higham J.M., et al. Changes in endometrial blood vessels in the endometrium of women with hormone replacement therapy-related irregular bleeding. Hum Reprod 18 (2003) 1100-1106
21. Hickey M., and Fraser I.S. Clinical implications of disturbances of uterine vascular morphology and function. Best Pract Res Clin Obstet Gynaecol 14 6 (2000) 937-951
22. Hickey M., and Fraser I. Human uterine vascular structures in normal and diseased states. Microsc Res Tech 60 4 (2003) 377-389
23. Johannisson E., Holinka C.F., and Arrenbrecht S. Transdermal sequential and continuous hormone replacement regimens with estradiol and norethisterone acetate in postmenopausal women: effects on the endometrium. Int J Fertil Womens Med 42 Suppl. 2 (1997) 388-398
24. Markee J.E. Menstruation in intraocular endometrial transplants in the Rhesus monkey. Am J Obstet Gynecol 131 5 (1978) 558-559
25. Hickey M., Dwarte D., and Fraser I.S. Superficial endometrial vascular fragility in Norplant users and in women with ovulatory dysfunctional uterine bleeding. Hum Reprod 15 7 (2000) 1509-1514
26. Thomas A.M., Hickey M., and Fraser I.S. Disturbances of endometrial bleeding with hormone replacement therapy. Hum Reprod 15 (2000) 7-17
27. Hickey M., and d'Arcangues C. Mechanisms underlying menstrual bleeding disturbances with progestogens. Ernst Schering Res Found Workshop 52 (2005) 191-217
28. Charnock-Jones D.S., Macpherson A.M., Archer D.F., et al. The effect of progestins on vascular endothelial growth factor, oestrogen receptor and progesterone receptor immunoreactivity and endothelial cell density in human endometrium. Hum Reprod 15 Suppl. 3 (2000) 85-95
29. Hickey M., Doherty D.A., Fraser I.S., Sloboda D.M., and Salamosen L.A. Why does menopausal hormone therapy (HT) lead to irregular uterine bleeding? Changes to endometrial blood vessels. Hum Reprod (January, 2008)
30. Rogers P.A., Plunkett D., and Affandi B. Perivascular smooth muscle alpha-actin is reduced in the endometrium of women with progestin-only contraceptive breakthrough bleeding. Hum Reprod 15 Suppl. 3 (2000) 78-84
31. Hickey M., Simbar M., Markham R., et al. Changes in vascular basement membrane in the endometrium of Norplant users. Hum Reprod 14 3 (1999) 716-721
32. Runic R., Schatz F., Wan L., Demopoulos R., Krikun G., and Lockwood C.J. Effects of norplant on endometrial tissue factor expression and blood vessel structure. J Clin Endocrinol Metab 85 10 (2000) 3853-3859
33. Jabbour H.N., Kelly R.W., Fraser H.M., and Critchley H.O. Endocrine regulation of menstruation. Endocr Rev 27 (2006) 17-46
34. Milling S.O., and Critchley. Progestogen only contraception and endometrial break through bleeding. Angiogenesis 8 (2005) 117-126
35. Bamberger A.M., Milde-Langosch K., Loning T., and Bamberger C.M. The glucocorticoid receptor is specifically expressed in the stromal compartment of the human endometrium. J Clin Endocrinol Metab 86 (2001) 5071-5074
36. Mertens H.J., Heineman M.J., Theunissen P.H., de Jong F.H., and Evers J.L. Androgen, estrogen and progesterone receptor expression in the human uterus during the menstrual cycle. Eur J Obstet Gynecol Reprod Biol 98 (2001) 58-65
37. Vani S., Critchley H.O., Fraser I.S., and Hickey M. Endometrial expression of steroid receptors in postmenopausal hormone replacement therapy users: relationship to bleeding patterns. J Fam Plann Reprod Health Care 34 1 (2008) 27-34
38. Krikun G., Schatz F., Taylor R., et al. Endometrial endothelial cell steroid receptor expression and steroid effects on gene expression. J Clin Endocrinol Metab 90 3 (2005) 1812-1818
39. Dahmoun M., Odmark I.S., Risberg B., Karlsson M.G., Pavlenko T., and Backstrom T. Apoptosis, proliferation, and sex steroid receptors in postmenopausal endometrium before and during HRT. Maturitas 49 (2004) 114-123
40. Salamonsen L.A., and Lathbury L.J. Endometrial leukocytes and menstruation. Hum Reprod Update 6 1 (2000) 16-27
41. Birkedal-Hansen H., Moore W.G., Bodden M.K., et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 4 2 (1993) 197-250
42. Vassilev V., Pretto C.M., Cornet P.B., et al. Response of matrix metalloproteinases and tissue inhibitors of metalloproteinases messenger ribonucleic acids to ovarian steroids in human endometrial explants mimics their gene- and phase-specific differential control in vivo. J Clin Endocrinol Metab 90 10 (2005) 5848-5857
43. Zhang J., Hampton A.L., Nie G., and Salamonsen L.A. Progesterone inhibits activation of latent matrix metalloproteinase (MMP)-2 by membrane-type 1 MMP: enzymes coordinately expressed in human endometrium. Biol Reprod 62 1 (2000) 85-94
44. Zhang J., and Salamonsen L.A. In vivo evidence for active matrix metalloproteinases in human endometrium supports their role in tissue breakdown at menstruation. J Clin Endocrinol Metab 87 5 (2002) 2346-2351
45. Skinner J.L., Riley S.C., Gebbie A.E., Glasier A.F., and Critchley H.O. Regulation of matrix metalloproteinase-9 in endometrium during the menstrual cycle and following administration of intrauterine levonorgestrel. Hum Reprod 14 3 (1999) 793-799
46. Marbaix E., Vekemans M., Galant C., et al. Circulating sex hormones and endometrial stromelysin-1 (matrix metalloproteinase-3) at the start of bleeding episodes in levonorgestrel-implant users. Hum Reprod 15 Suppl. 3 (2000) 120-134
47. Vincent A.J., Zhang J., Ostor A., et al. Decreased tissue inhibitor of metalloproteinase in the endometrium of women using depot medroxyprogesterone acetate: a role for altered endometrial matrix metalloproteinase/tissue inhibitor of metalloproteinase balance in the pathogenesis of abnormal uterine bleeding?. Hum Reprod 17 5 (2002) 1189-1198
48. Song J.Y., Russell P., Markham R., Manconi F., and Fraser I.S. Effects of high dose progestogens on white cells and necrosis in human endometrium. Hum Reprod 11 8 (1996) 1713-1718
49. Vincent A.J., and Salamonsen L.A. The role of matrix metalloproteinases and leukocytes in abnormal uterine bleeding associated with progestin-only contraceptives. Hum Reprod 15 Suppl. 3 (2000) 135-143
50. Hickey M., Higham J., Sullivan M., Miles L., and Fraser I.S. Endometrial bleeding in hormone replacement therapy users: preliminary findings regarding the role of matrix metalloproteinase 9 (MMP-9) and tissue inhibitors of MMPs. Fertil Steril 75 2 (2001) 288-296
51. Hickey M., Crewe J., Fraser I.S., Doherty D., and Salamonsen L.A. Mechanisms of irregular bleeding with hormone therapy: the role of matrixmetalloproteinases and their tissue inhibitors. J Clin Endocrinol Metab 91 8 (2006) 3189-3198
52. Murphy A.N., Unsworth E.J., and Stetler-Stevenson W.G. Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J Cell Physiol 157 2 (1993) 351-358
53. Critchley H.O., Kelly R.W., Baird D.T., and Brenner R.M. Regulation of human endometrial function: mechanisms relevant to uterine bleeding. Reprod Biol Endocrinol 4 Suppl. 1 (2006) S5
54. Hickey M., Crewe J., Goodridge J.P., et al. Menopausal hormone therapy and irregular endometrial bleeding: a potential role for uterine natural killer cells?. J Clin Endocrinol Metab 90 10 (2005) 5528-5535
55. Popovici R.M., Irwin J.C., Giaccia A.J., and Giudice L.C. Hypoxia and cAMP stimulate vascular endothelial growth factor (VEGF) in human endometrial stromal cells: potential relevance to menstruation and endometrial regeneration. J Clin Endocrinol Metab 84 6 (1999) 2245-2248
56. Sharkey A.M., Day K., McPherson A., et al. Vascular endothelial growth factor expression in human endometrium is regulated by hypoxia. J Clin Endocrinol Metab 85 1 (2000) 402-409
57. Krikun G., Schatz F., Finlay T., et al. Expression of angiopoietin-2 by human endometrial endothelial cells: regulation by hypoxia and inflammation. Biochem Biophys Res Commun 275 1 (2000) 159-163
58. Maisonpierre P.C., Suri C., Jones P.F., et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277 5322 (1997) 55-60
59. Bulger E.M., and Maier R.V. Antioxidants in critical illness. Arch Surg 136 10 (2001) 1201-1207
60. Hickey M., Dwarte D., and Fraser I.S. Precise measurements of intrauterine vascular structures at hysteroscopy in menorrhagia and during Norplant use. Hum Reprod 13 11 (1998) 3190-3196
61. Hickey M., Carati C., Manconi F., Gannon B.J., Dwarte D., and Fraser I.S. The measurement of endometrial perfusion in norplant users: a pilot study. Hum Reprod 15 5 (2000) 1086-1091
62. Hickey M., Krikun G., Carati C., and Lockwood C.J. LTPOC results in endometrial vasomotor instability hypoxia/reperfusion and bleeding 212A(number394) (2005), SGI, Los Angeles
63. Peeyananjarassri K., and Baber R. Effects of low-dose hormone therapy on menopausal symptoms, bone mineral density, endometrium, and the cardiovascular system: a review of randomized clinical trials. Climacteric 8 March(1) (2005) 13-23
64. Fan X., Krieg S., Kuo C., et al. VEGF blockade inhibits angiogenesis and reepithelialization of endometrium. FASEB J 22 10 (2008) 3571-3580